B

Sirpa Leppä1,2, Leo Meriranta1,2, Maare Arffman1,2

  • 1Department of Oncology Helsinki University Hospital Comprehensive Cancer Centre Helsinki Finland.

HemaSphere
|May 13, 2025
PubMed
概括

高风险的大型B细胞淋巴瘤 (LBCL) 患者在生物标志物导向治疗后的生存率有所改善. 循环瘤DNA (ctDNA) 和TP53状态是治疗反应的关键预后指标.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K